Sidney Kimmel Cancer Center Researchers to Present at AACR Annual Meeting 2019


Scientists will present new findings on topics including treatment outcomes, new drug targets, cancer health disparities, & drug resistance

Researchers from the Sidney Kimmel Cancer Center – Jefferson Health (SKCC) and Thomas Jefferson University will be participating in the American Association for Cancer Research (AACR) Annual Meeting 2019 in Atlanta, March 29-April 3. Studies and discussions led by SKCC and Jefferson researchers are listed below.

March 31

Clinical Trials Minisymposium: Advances in Novel Immunotherapeutics
Abstract CT038 – Results of a Phase Ib trial of an autologous cell vaccine for newly diagnosed glioblastoma
Presenter: David Andrews, MD
Location: Room A411
Time: 4:05-4:20 p.m.

1-5 p.m.

Late-Breaking Clinical Research: Clinical Research 1/Endocrinology
Abstract LB-024 – Inactivation of the 25-hydroxyvitamin D(3)-1(alpha)-hydroxylase gene (CYP27B1): evidence for impaired vitamin D signaling in an MMTV-PYMT mouse model of breast cancer
Section 41, Poster 16
Sylvester Jusu, John Presley, Bertrand Jean-Claude, Ursula Stochaj, Richard Kremer

Brain Cancers and Neuroblastoma
Abstract 243 – Differential effects of combination treatment of biochanin A and statins on glioblastoma multiforme cell proliferation and cell metabolism
Section 10, Poster 6
Vilas S. Desai, Eric Buchhalter, Max Cabanzo, Arushi Tiwari, Gagan Kaushal, James C. K. Lai, Alok Bhushan

Drug Targets in the Microenvironment
Abstract 112 – Patient derived models reveal impact of the tumor microenvironment on therapeutic response
Section 5, Poster 16
Ayesha A. Shafi, Matthew J. Schiewer, Renée de Leeuw, Emanuela Dylgjeri, Peter A. McCue, Neelima Shah, Leonard Gomella, Costas Lallas, Edouard Trabulsi, Margaret Centerera, Theresa Hickey, Lisa Butler, Ganesh Raj, Wayne Tilley, Edna Cukierman, Karen E. Knudsen


April 1

Minisymposium: Invasion and Metastasis 1: Cell-Intrinsic
Session chair: Andrew Aplin, PhD
Location: Room A305
Time: 3-5 p.m.

8 a.m. – noon

Signaling Pathways in Cancer Metabolism
Abstract 1851 – Novel roles of DNA-PK in metabolic regulation in prostate cancer
Section 39, Poster 24
Emanuela Dylgjeri
, Jonathan Goodwin, Ayesha Shafi, Vishal Kothari, Giorgia Zadra, Erin Seifert, Felix Feng, Karen Knudsen

1-5 p.m.

Adoptive Cell Therapy 2
Abstract 2319 – Accumulation and anti-tumor effect of chimeric antigen receptor (CAR) NK cells in metastasis uveal melanoma
Section 22, Poster 18
Bao Quoc Lam
, Takahito Sugase, Mizue Terai, Meggie Danielson, Nadezhda Anikeyeva, Melissa A. Wilson, Yuri Sykulev, Takami Sato

Cancer and Inflammation
Abstract 2339 – High fat diet modulates host immunity and impairs the efficacy of combined radiation and immunotherapy
Section 23, Poster 8
Gregor Manukian
, Brittany A. Simone, Tiziana DeAngelis, Kevin Ko, Charles Kivolowitz, Sylvester Jusu, Nicole L. Simone

Tumor-stroma Interactions
Abstract 2036 – Osteoblasts use multiple mechanisms of cellular communication to regulate breast cancer cell proliferation in bone

Section 8, Poster 17
Alexus D. Kolb, Alison B. Shupp, Dimpi Mukhopdhyay, Karen M. Bussard

Early Detection and Risk Prediction
Abstract 2422 – Discordant opinions about cancer screening for the LGBTQ+ community

Section 26, Poster 17
Kevin Ko
, Jerry Chen, Amy E. Leader, Marissa Ruggiero, Brittany A. Simone, Edith Mitchell, Nicole L. Simone


April 2

Minisymposium: Factors Influencing Cancer Outcomes
Abstract 4469 – Clinical outcomes among patients treated with abiraterone acetate for advanced prostate cancer with pre-existing cardiovascular conditions
Presenter: Grace Lu-Yao, PhD, MPH
Location: Room A404
Time: 4:05-4:20 p.m.

Minisymposium: Oncogenes, Tumor Suppressors, and Carcinogenesis
Abstract 4511 – Prostate cancer-specific enrichment of TP53 missense mutations elicits differential, context-dependent biochemical and biologic outcomes
Presenter: Jennifer McCann
Location: Room A313
Time: 4:05-4:20 p.m.

Special Session: Making Science Count for Patients: CDK4/6
CDK4/6 inhibitors: Evolving data outside breast cancer
Presenter: Jessica Teh, PhD
Location: Room B312
Time: 5:50-6:15 p.m.

8 a.m. – noon

New Target Identification
Abstract 3085 – Recharacterizing the FDA approved drug pyrvinium pamoate as clinically relevant HuR inhibitor in pancreatic ductal adenocarcinoma
Section 13, Poster 20
Christopher W. Schultz, Teena Dhir, Samantha Z. Brown, Saswati Chand, Wei Jiang, Grace A. McCarthy, Alex O. Haber, Charles J. Yeo, Austin Goetz, Avinoam Nevler, Oloruntoba Bolaji, Jonathan R. Brody

Science and Health Policy 1
Abstract 3338 – Understanding the effect of racial disparities on patients response to dietary intervention during cancer therapy

Section 29, Poster 4
Sylvester Jusu
, Kaitlyn Dykes, Kevin Ko, Tiziana DeAngelis, Edith Mitchell, Nicole Simone

1-5 p.m.

Biomarkers and Immune Monitoring
Abstract 4052 – Cytokines and chemokines production after radiosphere treatment for uveal melanoma patients with hepatic metastases
Section 22, Poster 15
Mizue Terai
, Emma Link, Carin F. Gonsalves, David J. Eschelman, Robert D. Adamo, Meggie Danielson, Marlana M. Orloff, Takami Sato

Post-transcriptional and Translational Control of Gene Regulation
Abstract 4388 – A novel, reversible YAP1-HuR axis promotes pancreatic tumorigenesis
Section 36, Poster 6
Samantha Z. Brown
, Christopher W. Schultz, Tianyun Li, Aditi Jain, Raymond O’Neill, Wei Jiang, Charles P. Yeo, Jonathan R. Brody

Drug Delivery and Nanoparticles
Abstract 3614 – Targeted 3DNA-siHuR nanocarrier therapy for pancreatic ductal adenocarcinoma
Section 1, Poster 2
Grace McCarthy, Christopher Schultz, Aditi Jain, Teena Dhir, Charles Yeo, Jessica Bowers, Lou Casta, Kelly Rhodes, Lori Getts, Robert Getts, Trevor Baybutt, Adam Snook, Jonathan Brody


April 3

8 a.m. – noon

Mechanisms and Consequences of Transcriptional Deregulation
Abstract 5217 – RB loss reprograms AR and E2F1 signaling in models of prostate cancer progression
Section 36, Poster 18
Amy C. Mandigo
, Chris McNair, Matthew J. Schiewer, Karen E. Knudsen

Drug Resistance 6
Abstract 4764 – A global transcriptome analysis of pancreatic cancer cells distinguishes between acute and acquired PARP inhibitor resistance mechanisms
Section 11, Poster 25
Aditi Jain
, Matthew McCoy, Lebaron A. Agostini, Yuriy Gusev, Subha Madhavan, Michael Pishvaian, Sankar Addya, Eric Londin, Maria R. Gurevich, Chani Stossel, Talia Golan, Charles J. Yeo, Jonathan R. Brody


Lauren Riley
215-503-4277 (o)
412-559-5553 (c)